|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 8.830 SEK | -0.67% |
|
-7.35% | -34.59% |
| 09-17 | Vivesto sees tumor effect with Paccal Vet in cat study | FW |
| 09-17 | Vivesto reports positive topline results from the Paccal Vet feline study | FW |
| Market Cap | 97.76M 9.86M 8.66M 8.13M 7.44M 13.91M 944M 14.02M 37.85M 482M 37.03M 36.22M 1.57B | P/E 2026 * |
-2.93x | P/E 2027 * | -2.44x |
|---|---|---|---|---|---|
| Enterprise Value | 89.76M 9.05M 7.95M 7.46M 6.83M 12.77M 867M 12.87M 34.75M 443M 34M 33.25M 1.44B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
52.67% | Yield 2026 * |
-
| Yield 2027 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| VIVE | Delayed | |
Deutsche Boerse AG
| OMA | Delayed | |
|
CBOE
| 0N4A | Real-time | |
|
CBOE
| OASMs | Real-time | |
|
Börse Stuttgart
| OMA | Delayed |
Last Transcript: Vivesto AB
| 1 day | -0.67% | ||
| 1 week | -7.35% | ||
| Current month | -0.11% | ||
| 1 month | +0.11% | ||
| 3 months | -0.67% | ||
| 6 months | +9.28% | ||
| Current year | -34.59% |
| 1 week | 8.82 |  | 9.73 |
| 1 month | 8.7 | | 10 |
| Current year | 7 | | 19.5 |
| 1 year | 7 | | 27.3 |
| 3 years | 7 | | 90.6 |
| 5 years | 7 | | 302.9 |
| 10 years | 7 | | 1,670 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 68 | 2023-01-22 |
Björn Svanström
DFI | Director of Finance/CFO | 55 | 2026-06-30 |
| Chief Tech/Sci/R&D Officer | 39 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 2022-05-24 | |
Hege Hellstrom
BRD | Director/Board Member | 61 | 2019-09-25 |
Pål Ryfors
BRD | Director/Board Member | 43 | 2022-05-24 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/25/22 | Buy | Chief Executive Officer | 12,200 | 0.0027% | ||
| 3/24/22 | Others | Chairman | 120,000 | 0.0268% | ||
| 12/20/21 | Free | Chief Executive Officer | 2,250,000 | 0.5018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | -7.35% | -60.40% | -61.27% | 9.98M | |
| -1.64% | +1.31% | +52.46% | +109.07% | 1,043B | |
| -0.01% | +0.74% | +54.51% | +67.71% | 649B | |
| -0.05% | +0.78% | +19.09% | +73.55% | 469B | |
| -0.25% | +0.72% | +33.97% | +45.63% | 355B | |
| +0.98% | +3.30% | +19.63% | +27.91% | 270B | |
| -1.91% | +2.59% | +8.09% | +12.53% | 262B | |
| -1.01% | +8.10% | +41.99% | +51.70% | 222B | |
| -0.85% | +3.47% | +34.56% | +101.80% | 189B | |
| -2.53% | -8.57% | -34.17% | -60.67% | 175B | |
| Average | -0.15% | +1.31% | +16.97% | +36.79% | 363.3B | |
| Weighted average by Cap. | +0.19% | +2.19% | +35.33% | +65.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -31M -3.13M -2.75M -2.58M -2.36M -4.41M -299M -4.44M -12M -153M -11.74M -11.49M -499M | -40M -4.03M -3.54M -3.33M -3.05M -5.69M -386M -5.73M -15.49M -197M -15.15M -14.82M -644M |
| Net Debt | -8M -807K -709K -665K -609K -1.14M -77.25M -1.15M -3.1M -39.48M -3.03M -2.96M -129M | -17M -1.71M -1.51M -1.41M -1.29M -2.42M -164M -2.44M -6.58M -83.89M -6.44M -6.3M -274M |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-23 | SEK 8.830 | -0.67% | 5,449 |
| 26-09-22 | SEK 8.890 | -1.44% | 6,068 |
| 26-09-21 | SEK 9.020 | -0.99% | 6,141 |
| 26-09-18 | SEK 9.110 | -2.04% | 2,912 |
| 26-09-17 | SEK 9.300 | +0.65% | 11,957 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VIVE Stock
Select your edition
All financial news and data tailored to specific country editions
